Fully Human Antibody / TCR Platforms

Hu-VHH Antibody

Single VHH (variable heavy domain of heavy chain) domain, is half the size of scFv (single-chain fragment variable) proteins, enabling better tumor and blood-brain barrier penetration. Their simple structure simplifies manufacturing, making them ideal for bispecific antibodies and cell therapies.
  • 200+
    Hu-VHH Projects
  • 450+
    Antibody Asset Partnerships

on this page

  • Advantages of Biocytogen's Novel Hu-VHH Platform
  • Biocytogen's RenNano-based Hu-VHH Platform
  • Off-the-shelf Hu-VHHs Available for Partnership
  • FAQs

Webinars

View All

    Posters

    View All

      Advantages of Biocytogen's Novel Hu-VHH Platform

      • The Single VHH (variable heavy domain of heavy chain) is only half the size of scFv (single-chain fragment variable) proteins, enabling better penetration of solid tumors and the blood-brain barrier.
      • Based on RenNano, fully human heavy-chain antibodies (HCAbs) or fully human VHH (Hu-VHH) do not require humanization in vitro, resulting in a faster and more cost-effective antibody discovery process.
      • It can produce fully human HCAbs with sequence diversity, good affinity, and favorable pharmacokinetic properties.
      • Compared with scFv-based formats, the compact architecture of Hu-VHH enables greater design flexibility and simplified molecular engineering, which is particularly advantageous for complex modalities such as bispecific/multispecific antibodies and cell therapies.
      Advantages of Biocytogen's Novel Hu-VHH Platform

      Biocytogen's RenNano-based Hu-VHH Platform

      Hu-VHH developed from RenNano.
      Hu-VHH developed from RenNano Hu-VHH developed from RenNano 2
      Using RenNano, Biocytogen is creating a Hu-VHH antibody library for high-potential therapeutic targets including tumor-associated antigens, GPCRs, immune checkpoints, cytokine/chemokines, and factors related to neurological diseases.
      Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale Hu-VHH development abilities with collaborators’ expertise in Hu-VHH-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs, and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.

      Off-the-shelf Hu-VHHs Available for Partnership

      Therapeutic Area Target(s) Immunization
      • Development
      • Hits
        selection
        Leads
        selection
        Candidate
        selection
      Preclinical IND
      Oncology VEGFA
      4-1BB
      CD98
      ILЗRA
      MUC16
      OX40
      ADAM9
      CD28
      CD38
      CD3e
      CD71
      DLL3
      EPHA2
      FAP
      GPRC5D
      GUCY2C
      HER3
      IL6R
      MSLN
      Nectin-4
      PD-L1
      PSMA
      PTK7
      ROR1
      TROP2
      Infectious Diseases RSV
      Metabolism CD38

      Frequently Asked Questions (FAQs) About Hu-VHH Platform

      1. What is a VHH antibody?

      A VHH antibody is a single-domain antibody derived from the variable region of HCAbs. It independently recognizes and binds an antigen without a light chain. With a molecular weight of approximately 12-15 kDa, VHHs represent compact antigen-binding units that can serve as building blocks for diverse therapeutic antibody formats.

      2. What are the key advantages of VHH antibodies?

      VHH antibodies are compact single-domain binders with advantages in flexible molecular engineering and tissue penetration, especially in solid tumors and blood-brain barrier (BBB). RenNano®-derived fully human VHHs also offer diverse CDR3 sequences, good specificity and affinity, and robust biological activity in both in vitro and in vivo studies.

      3. How does Biocytogen discover and select fully human VHH antibody candidates?

      Following immunization of RenNano® mice, Biocytogen identifies VHH candidates efficiently through high-throughput Beacon B-cell sorting or AI-powered RenSuper™ antibody discovery platform. AI-prioritized candidates subsequently undergo experimental validation for properties including binding, affinity, developability, and cross-reactivity.

      4. What therapeutic targets does Biocytogen’s fully human VHH platform cover?

      Biocytogen’s fully human VHH (Hu-VHH) platform covers therapeutic targets including tumor-associated antigens, GPCRs, immune checkpoints, cytokines and chemokines, and targets related to neurological diseases. The platform also supports VHH discovery for blood-brain barrier (BBB) penetration and in vivo CAR-T delivery, expanding the potential applications of fully human VHH antibodies.

      5. Why are Hu-VHHs well suited as building blocks for bispecific and multispecific therapeutics?

      VHHs/HCAbs bind antigens without light chains, reducing risk of heavy-light chain mispairing. Their compact, modular structure makes them flexible building blocks for bispecific and multispecific antibody engineering. For example, in multispecific ADC design, a heavy-chain-only binder can serve as one targeting arm and be paired with a Fab, another HCAb, or other antibody formats to introduce additional binding specificities while simplifying molecular assembly.

      6. When should drug developers choose a HCAb versus a single VHH format?

      The choice depends on the intended therapeutic application. HCAb formats retain an Fc region for FcRn-mediated recycling and extended pharmacokinetics. They suit applications requiring sustained exposure, including immune cell engagers, bispecific or multispecific antibodies. Single VHH formats offer compact size and flexible integration into multispecific antibodies, conjugates, and CAR-T constructs. Their small size can improve tissue access and recognition of challenging epitopes.